Merck Serono follows up F-Star investment with deal worth €492 million
This article was originally published in Scrip
Executive Summary
F-Star has signed a research, licence and commercialisation agreement with Merck Serono for the discovery of new antibody-derived therapeutics against inflammatory disease targets using F-Star's Modular Antibody Technology that could be worth up to €492 million to the small biotech company.